Skip to main content

Advertisement

Table 3 Multivariate analysis for progression free survival in our cohort

From: EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

CharacteristicsMultivariate analyses
HR (95% CI)P value
Model 1
 TP53 status
  Mutated1.00 (Reference) 
  Wild type0.66 (0.31–1.43)0.298
 T790M RMA (continuous)1.14 (0.49–2.66)0.766
 T790M RMP (continuous)0.15 (0.03–0.79)0.025
Model 2
 TP53 status
  Mutated1.00 (Reference) 
  Wild type0.58 (0.28–1.24)0.161
 T790M RMA (categorical)
  ≤ 0.301.00 (Reference) 
  > 0.300.71 (0.31–1.61)0.409
 T790M RMP (categorical)
  ≤ 0.241.00 (Reference) 
  > 0.240.46 (0.20–1.05)0.066
  1. HR hazard ratio, CI confidence interval, RMA Relative mutation abundance, RMP Relative mutation purity